Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial — Muthiah Vaduganathan (2017) | RDL Network
Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial
Article 2017 en
Authors
MV
Muthiah Vaduganathan
BC
Baljash Cheema
EC
Erin R. Cleveland
Abstract
1 min read
Plasma renin activity is reduced early and durably by aliskiren, but this did not translate into improved clinical outcomes in ASTRONAUT. Baseline PRA or short-term reduction in PRA do not identify a subgroup who may preferentially benefit from direct renin inhibition. Clinical Trial Registration ClinicalTrials.gov Unique Identifier: NCT00894387.
Muthiah Vaduganathan, Baljash Cheema, Erin R. Cleveland, K. Nathan Sankar, Haris Subačius, Gregg C. Fonarow, Scott D. Solomon, Eldrin F. Lewis, Stephen J. Greene, Aldo Maggioni, Michael Böhm, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
Aldo Maggioni, Sally Greene, Gregg C. Fonarow, Michael Böhm, Faı̈ez Zannad, Scott D. Solomon, E. F. Lewis, Fabio Baschiera, Tien Hua, Claudio Gimpelewicz, Anastasia Lesogor, Mihai Gheorghiade, S. Ramos, Antoni Bayés de Luna, Santiago Miriuka, Maria Canto Diez, Enrico Perna, Hugo A Luquez, J. G. Pinna, Jorge Castagnino, Pedro Alvarenga, Joaquı́n Ibáñez, Edwin Blumberg, Claudio Dizeo, Rodolfo A. Ahuad Guerrero, Pablo Schygiel, R. Milesi, Cecilia Sosa, Miguel Hominal, Leopoldo Márquez, C. Poy, Eduardo Hasbani, Manuel Vico,
Stephen J. Greene, Gregg C. Fonarow, Scott D. Solomon, Haris Subačius, Muthiah Vaduganathan, Andrew P. Ambrosy, Marat Fudim, Michael Böhm, Aldo Maggioni, Eldrin F. Lewis, Faı̈ez Zannad, Javed Butler
Discussion(0)
No comments yet. Be the first to comment.